PH31420A - Methods of use for inhibiting bone loss and lowering serum cholesteol. - Google Patents

Methods of use for inhibiting bone loss and lowering serum cholesteol.

Info

Publication number
PH31420A
PH31420A PH49963A PH49963A PH31420A PH 31420 A PH31420 A PH 31420A PH 49963 A PH49963 A PH 49963A PH 49963 A PH49963 A PH 49963A PH 31420 A PH31420 A PH 31420A
Authority
PH
Philippines
Prior art keywords
cholesteol
methods
bone loss
inhibiting bone
lowering serum
Prior art date
Application number
PH49963A
Other languages
English (en)
Inventor
Michael W Draper
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22760425&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH31420(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PH31420A publication Critical patent/PH31420A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PH49963A 1994-03-02 1995-02-14 Methods of use for inhibiting bone loss and lowering serum cholesteol. PH31420A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/205,012 US5478847A (en) 1994-03-02 1994-03-02 Methods of use for inhibiting bone loss and lowering serum cholesterol

Publications (1)

Publication Number Publication Date
PH31420A true PH31420A (en) 1998-10-29

Family

ID=22760425

Family Applications (1)

Application Number Title Priority Date Filing Date
PH49963A PH31420A (en) 1994-03-02 1995-02-14 Methods of use for inhibiting bone loss and lowering serum cholesteol.

Country Status (23)

Country Link
US (5) US5478847A (no)
EP (1) EP0674903A1 (no)
JP (3) JP2818384B2 (no)
KR (1) KR950031069A (no)
CN (1) CN1119530A (no)
AU (1) AU702575B2 (no)
BR (1) BR9500784A (no)
CA (1) CA2141999A1 (no)
CO (1) CO4340681A1 (no)
CZ (1) CZ31395A3 (no)
HU (1) HUT72638A (no)
IL (1) IL112593A0 (no)
MY (1) MY130157A (no)
NO (1) NO950774L (no)
NZ (2) NZ314699A (no)
PE (1) PE44895A1 (no)
PH (1) PH31420A (no)
PL (1) PL307463A1 (no)
RU (2) RU2100024C1 (no)
SG (1) SG46354A1 (no)
UA (1) UA32636C2 (no)
YU (1) YU13695A (no)
ZA (1) ZA95976B (no)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
USRE39049E1 (en) 1992-07-28 2006-03-28 Eli Lilly And Company Methods for inhibiting bone loss
USRE38968E1 (en) * 1992-07-28 2006-02-07 Eli Lilly And Company Methods for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl-4-[2-(piperidin-1-yl) ethoxyphenylimethanone hydrochloride
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
US5770609A (en) 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
ATE406909T1 (de) 1993-05-13 2008-09-15 Poniard Pharmaceuticals Inc Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind
US6319914B1 (en) 1993-11-05 2001-11-20 Apollo Biopharmaceuticals, Inc. Cytoprotective effect of polycyclic phenolic compounds
US5554601A (en) * 1993-11-05 1996-09-10 University Of Florida Methods for neuroprotection
US5478847A (en) 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
US5512583A (en) * 1995-01-30 1996-04-30 Eli Lilly And Company Methods of decreasing serum calcium levels
US5856340A (en) 1995-02-28 1999-01-05 Eli Lilly And Company Method of treating estrogen dependent cancers
CA2223595C (en) 1995-06-07 2008-08-05 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
US5726168A (en) * 1995-10-12 1998-03-10 Eli Lilly And Company Lipophilic benzothiophenes
WO1997035571A1 (en) * 1996-03-26 1997-10-02 Eli Lilly And Company Benzothiophenes, formulations containing same, and methods
US6458811B1 (en) * 1996-03-26 2002-10-01 Eli Lilly And Company Benzothiophenes formulations containing same and methods
US6440421B1 (en) * 1996-04-18 2002-08-27 Auchkland Uniservices Limited Treatment of bone disorders with adrenomedullin or adrenomedullin agonists
US5888963A (en) * 1996-04-18 1999-03-30 Auckland Uniservices Limited Treatment of bone disorders with adrenomedullin
US5747509A (en) * 1996-06-03 1998-05-05 Schering Aktiengesellschaft Method for lowering plasma levels of lipoprotein(a)
WO1997048694A1 (en) * 1996-06-20 1997-12-24 Board Of Regents, The University Of Texas System Compounds and methods for providing pharmacologically active preparations and uses thereof
CA2219377A1 (en) * 1996-10-30 1998-04-30 Eli Lilly And Company Improvements in or relating to the prophylaxis of breast cancer
GB9624800D0 (en) * 1996-11-29 1997-01-15 Lilly Co Eli Methods of preventing breast cancer
KR19980033284A (ko) * 1996-10-30 1998-07-25 피터지.스트링거 개선된 유방암 예방법
KR100522646B1 (ko) * 1996-10-30 2005-12-21 일라이 릴리 앤드 캄파니 유방암의예방방법
US6069175A (en) * 1996-11-15 2000-05-30 Pfizer Inc. Estrogen agonist/antagonists treatment of atherosclerosis
ATE348589T1 (de) 1997-09-26 2007-01-15 Auckland Uniservices Ltd Verwendung von amylin, adrenomedullin und deren analoga zur behandlung von knorpeldefekten
US6096781A (en) 1997-11-14 2000-08-01 Eli Lilly And Company 2-arylbenzo[B]thiophenes useful for the treatment of estrogen deprivation syndrome
US6054446A (en) 1997-12-24 2000-04-25 Sri International Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
CN1304290A (zh) * 1998-04-08 2001-07-18 伊莱利利公司 雷洛昔芬的肺和鼻传递给药
US20040186185A1 (en) * 1998-05-07 2004-09-23 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6087378A (en) * 1998-10-13 2000-07-11 Eli Lilly And Company Pharmaceutical formulations and applications thereof for the treatment of estrogen deprivation syndrome
JP5005127B2 (ja) 1999-05-04 2012-08-22 ストラカン・インターナショナル・リミテッド アンドロゲングリコシド及びそのアンドロゲン作用活性
US6339078B1 (en) 1999-07-20 2002-01-15 University Of Florida Research Foundation, Inc. Methods of prevention and treatment of ischemic damage
US6326365B1 (en) 1999-07-20 2001-12-04 Apollo Biopharmaceutics, Inc. Methods of prevention and treatment of ischemic damage
US20020013327A1 (en) * 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
AR029538A1 (es) * 2000-07-06 2003-07-02 Wyeth Corp Composiciones farmaceuticas de agentes estrogenicos
EP1335727B1 (en) * 2000-10-25 2004-10-06 Eli Lilly And Company Method for inhibiting cataracts
US6599921B2 (en) 2001-02-22 2003-07-29 Nanodesign, Inc. Non-steroidal estrogen receptor ligands
EP1312363A1 (en) * 2001-09-28 2003-05-21 Pfizer Products Inc. Methods of treatment and kits comprising a growth hormone secretagogue
CN1649614A (zh) 2002-02-22 2005-08-03 新河药品股份有限公司 活性剂传递系统和保护及施用活性剂的方法
US7342884B2 (en) * 2002-03-13 2008-03-11 Harmonic, Inc. Method and apparatus for one directional communications in bidirectional communications channel
JP3887588B2 (ja) * 2002-08-30 2007-02-28 株式会社リガク Ｘ線回折による応力測定法
CA2499819A1 (en) 2002-09-30 2004-04-08 A/S Gea Farmaceutisk Fabrik Novel raloxifene acid addition salts and/or solvates thereof, improved method for purification of said raloxifene acid addition salts and/or solvates thereof and pharmaceutical compositions comprising these
US20060106010A1 (en) * 2003-05-27 2006-05-18 Black Larry J Methods for inhibiting bone loss
CN100496501C (zh) * 2003-09-19 2009-06-10 威斯康星州男校友研究基金会 包含2-亚烷基-19-去甲-维生素d衍生物与雌激素激动剂/拮抗剂的组合的药物组合物和方法
CA2549935A1 (en) * 2003-12-17 2005-07-07 Pfizer Products Inc. Treatment of conditions that present with low bone mass by continuous combination therapy with selective prostaglandin ep4 receptor agonists and an estrogen
US20050137264A1 (en) * 2003-12-22 2005-06-23 Patel Ashish A. Modafinil compositions
US20050203086A1 (en) * 2004-03-04 2005-09-15 Pfizer Inc. Methods of treatment using an EP2 selective receptor agonist
JP2007532557A (ja) * 2004-04-08 2007-11-15 ワイス バゼドキシフェンアセテート固体分散物製剤
BRPI0509385A (pt) * 2004-04-08 2007-09-18 Wyeth Corp composto, composição, métodos de preparar o sal, ea dispensão sólida, de tratar um mamìfero tendo uma doença ou sìndrome associadas com a deficiência de estrogênio ou excesso de estrogênio, uma doença ou distúrbio associados com a proliferação ou desenvolvimento anormal dos tecidos endometriais, de tratar cáncer de mama em um mamìfero, e uma mulher pós-menopáusica quanto a um ou mais distúrbios vasomotores, de reduzir colesterol, e de inibir perda óssea em um mamìfero, dispersão sólida, e, uso de um composto
US20060068010A1 (en) * 2004-09-30 2006-03-30 Stephen Turner Method for improving the bioavailability of orally delivered therapeutics
US8367105B2 (en) 2004-11-10 2013-02-05 Teva Pharmaceutical Industries, Ltd. Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
CA2587295A1 (en) * 2004-11-10 2006-05-18 Teva Pharmaceutical Industries Ltd. Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
UA89513C2 (uk) * 2004-12-03 2010-02-10 Элан Фарма Интернешнл Лтд. Стабільна композиція з наночастинок ралоксифену гідрохлориду
US20060270641A1 (en) * 2005-05-31 2006-11-30 Steiner Mitchell S Method for chemoprevention of prostate cancer
WO2009146097A1 (en) * 2008-04-02 2009-12-03 Dr. Reddy's Laboratories Ltd. Raloxifene pharmaceutical formulations
EP2448562B1 (en) 2009-07-02 2013-11-06 Synthon B.V. Raloxifene composition
US8501690B2 (en) 2010-04-30 2013-08-06 John G. Stark Use of selective estrogen receptor modulator for joint fusion and other repair or healing of connective tissue
JP5508311B2 (ja) * 2011-02-28 2014-05-28 テバ ファーマシューティカル インダストリーズ リミティド 低水溶性薬物とともに使用することによく適した圧縮固体状投与形態の製造方法およびそれにより製造された圧縮固体状投与形態
WO2013090921A1 (en) 2011-12-16 2013-06-20 Olema Pharmaceuticals, Inc. Novel benzopyran compounds, compositions and uses thereof
WO2014203129A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Combinations of benzopyran compounds, compositions and uses thereof
WO2014203132A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Substituted benzopyran compounds, compositions and uses thereof
PL3355884T3 (pl) 2015-10-01 2021-11-29 Olema Pharmaceuticals, Inc. Tetrahydro-1H-pirydo[3,4-b]indolowe leki antyestrogenowe
MX2018007079A (es) 2015-12-09 2018-11-12 The Board Of Trustees Of Univ Of Illinois Reguladores a la baja del receptor de estrogeno selectivo de benzotiofeno.
CN109562113A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的螺环降解决定子体
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
RU2019102647A (ru) 2016-07-01 2020-08-03 Г1 Терапьютикс, Инк. Антипролиферационные средства на основе пиримидина
WO2018081168A2 (en) 2016-10-24 2018-05-03 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective mixed estrogen receptor downregulators
BR112019013814A2 (pt) 2017-01-06 2020-01-21 G1 Therapeutics Inc método para tratamento de câncer ou de um tumor em um indivíduo, composição farmacêutica, combinação, e, kit.
JP2020507566A (ja) 2017-02-10 2020-03-12 ジー１ セラピューティクス， インコーポレイテッド ベンゾチオフェンエストロゲン受容体モジュレーター
WO2019006393A1 (en) 2017-06-29 2019-01-03 G1 Therapeutics, Inc. MORPHIC FORMS OF GIT38 AND METHODS OF MAKING SAME
WO2020132561A1 (en) 2018-12-20 2020-06-25 C4 Therapeutics, Inc. Targeted protein degradation
CN118344370A (zh) 2019-12-20 2024-07-16 C4医药公司 用于egfr降解的异吲哚啉酮和吲唑化合物
WO2024030968A1 (en) 2022-08-03 2024-02-08 Brystol-Myers Squibb Company Compounds for modulating ret protein
WO2024097989A1 (en) 2022-11-04 2024-05-10 Bristol-Myers Squibb Company Ret-ldd protein degraders
WO2024097980A1 (en) 2022-11-04 2024-05-10 Bristol-Myers Squibb Company Ret-ldd protein inhibitors

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4185108A (en) 1977-05-10 1980-01-22 Westwood Pharmaceuticals Inc. Antiosteoporotic agents
IL65379A0 (en) 1981-04-03 1982-05-31 Lilly Co Eli Process for preparing acylated benzothiophenes
GB2097788B (en) 1981-04-03 1985-04-24 Lilly Co Eli Benzothiophene compounds and process for preparing them
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
EP0068563A3 (en) 1981-06-23 1983-06-15 THE PROCTER & GAMBLE COMPANY Heterocyclic acetic acid compounds and compositions for treating bone diseases
US4729999A (en) 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency
US4970237A (en) 1987-03-20 1990-11-13 Yale University Use of clomiphene to increase bone mass in premenopausal women
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
US5208031A (en) 1989-06-06 1993-05-04 Kelly Patrick D Sexual lubricants containing zinc as an anti-viral agent
US5011853A (en) 1989-08-25 1991-04-30 Washington University Compounds for treatment of cholinergic neurotoxins
US5118667A (en) 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
DE4122484A1 (de) * 1991-07-06 1993-01-07 Teves Gmbh Alfred Schaltungsanordnung zur erkennung von radsensordefekten
DE4123368C1 (no) 1991-07-15 1992-11-05 Bergwerksverband Gmbh, 4300 Essen, De
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
WO1993011074A1 (en) * 1991-11-25 1993-06-10 Healthguard, Incorporated Multistage coaxial encapsulated filter assembly
TW366342B (en) 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
TW383306B (en) * 1992-12-22 2000-03-01 Lilly Co Eli New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol
US5482949A (en) 1993-03-19 1996-01-09 Eli Lilly And Company Sulfonate derivatives of 3-aroylbenzo[b]thiophenes
US5445941A (en) 1993-06-21 1995-08-29 Eli Lilly And Company Method for screening anti-osteoporosis agents
ATE157869T1 (de) 1993-06-24 1997-09-15 Lilly Co Eli Antiöstrogene 2-phenyl-3-aroylbenzothiophene als hypoglykämische mittel
TW303299B (no) 1993-07-22 1997-04-21 Lilly Co Eli
US5441947A (en) 1993-08-25 1995-08-15 Eli Lilly And Company Methods of inhibiting vascular restenosis
US5468773A (en) 1993-08-25 1995-11-21 Eli Lilly And Company Methods for inhibiting bone loss and cartilage degradation using wortmannin and its analogs
US5457116A (en) 1993-10-15 1995-10-10 Eli Lilly And Company Methods of inhibiting uterine fibrosis
US5461065A (en) 1993-10-15 1995-10-24 Eli Lilly And Company Methods for inhibiting endometriosis
RU2135176C1 (ru) 1993-12-14 1999-08-27 Эли Лилли Энд Компани Водорастворенный комплекс включения соединений бензотиофена с водорастворимым циклодекстрином, способ его получения и фармацевтическая композиция
US5462949A (en) 1993-12-21 1995-10-31 Eli Lilly And Company Methods of inhibiting fertility in women
US5591753A (en) 1994-01-28 1997-01-07 Eli Lilly And Company Combination treatment for osteoporosis
US5478847A (en) 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
US5811120A (en) 1994-03-02 1998-09-22 Eli Lilly And Company Solid orally administerable raloxifene hydrochloride pharmaceutical formulation
US5972383A (en) 1994-03-02 1999-10-26 Eli Lilly And Company Solid orally administerable raloxifene hydrochloride pharmaceutical formulation
CO4410190A1 (es) 1994-09-19 1997-01-09 Lilly Co Eli 3-[4-(2-AMINOETOXI)-BENZOIL]-2-ARIL-6-HIDROXIBENZO [b] TIOFENO CRISTALINO
US5629425A (en) 1994-09-19 1997-05-13 Eli Lilly And Company Haloalkyl hemisolvates of 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-piperidinoethoxy)-benzoyl]benzo[b]thiophene
US6458811B1 (en) 1996-03-26 2002-10-01 Eli Lilly And Company Benzothiophenes formulations containing same and methods
US6713494B1 (en) 1996-08-28 2004-03-30 Eli Lilly And Company Amorphous benzothiophenes, methods of preparation and methods of use
ID24978A (id) 1997-11-14 2000-08-31 Lilly Co Eli 2-ARYL-3-AROYLBENZO (b) THIOPHENES BERGUNA UNTUK PENGOBATAN SINDROM DEPRIVASI ESTROGEN
US6096781A (en) 1997-11-14 2000-08-01 Eli Lilly And Company 2-arylbenzo[B]thiophenes useful for the treatment of estrogen deprivation syndrome
US6087378A (en) 1998-10-13 2000-07-11 Eli Lilly And Company Pharmaceutical formulations and applications thereof for the treatment of estrogen deprivation syndrome

Also Published As

Publication number Publication date
US5610168A (en) 1997-03-11
CO4340681A1 (es) 1996-07-30
SG46354A1 (en) 1998-02-20
AU702575B2 (en) 1999-02-25
US5641790A (en) 1997-06-24
NO950774D0 (no) 1995-02-28
HU9500634D0 (en) 1995-04-28
CA2141999A1 (en) 1995-09-03
JP2818384B2 (ja) 1998-10-30
IL112593A0 (en) 1995-05-26
RU95102778A (ru) 1996-11-27
PL307463A1 (en) 1995-09-04
ZA95976B (en) 1996-08-07
JPH10291932A (ja) 1998-11-04
EP0674903A1 (en) 1995-10-04
BR9500784A (pt) 1995-10-24
RU2100024C1 (ru) 1997-12-27
AU1355195A (en) 1995-09-07
NO950774L (no) 1995-09-04
HUT72638A (en) 1996-05-28
UA32636C2 (uk) 2001-02-15
MY130157A (en) 2007-06-29
US5747510A (en) 1998-05-05
NZ314699A (en) 2000-07-28
JPH07267861A (ja) 1995-10-17
KR950031069A (ko) 1995-12-18
YU13695A (sh) 1999-07-28
USRE39050E1 (en) 2006-03-28
CZ31395A3 (en) 1995-11-15
JPH10310525A (ja) 1998-11-24
PE44895A1 (es) 1995-12-20
US5478847A (en) 1995-12-26
RU2150275C1 (ru) 2000-06-10
NZ270460A (en) 1999-07-29
CN1119530A (zh) 1996-04-03

Similar Documents

Publication Publication Date Title
PH31420A (en) Methods of use for inhibiting bone loss and lowering serum cholesteol.
HUP9904009A3 (en) Method and novel compounds for use therein
PL331900A1 (en) 1,4-heterocyclic inhibitors of metaloprotease
HUP9700602A3 (en) New inhibitors of bone-resorption and vitronectine-receptor-antagonists
PL331838A1 (en) 1,3-diheterocyclic inhibitors of metaloproteases
AU3955295A (en) Method and device for tissue resection
HU9401580D0 (en) Method for the preparation and popification of alphia - interferon
EP0751748A4 (en) SCALPEL
IL111224A0 (en) Methods for inhibiting bone loss
GB9520615D0 (en) Method of preventing bone loss
ZA971964B (en) Azolobenzazepine derivatives and compositions and method of use thereof.
AU2389600A (en) Reservoir-and-filter system and method of use
PH31270A (en) Superplasticizer-concrete composition and method of preparation.
GB2346823B (en) Reamer and method of using the same
HUP0103473A3 (en) Phosphoglycolipid and methods for its use
GB9621570D0 (en) Formulations and methods for inhibiting bone loss
IL114119A0 (en) Compositions and methods for the treatment of tumors
GB9420616D0 (en) Method, compositions and use
EP0799225A4 (en) COMPOUNDS AND RELATED METHODS
ZA957949B (en) Methods of inhibiting endometrial mitroses
PL331283A1 (en) Preparation for treating and/or preventing stupefaction
GB9616563D0 (en) Compounds and methods
EP0934345A4 (en) CONNECTIONS AND PROCEDURE
AU4402497A (en) Methods and means for the treatment of malignancies
ZA971816B (en) Method and novel compounds for use therein.